Omeros

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.

About OMER

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. 

CEO
Gregory A. Demopulos
CEOGregory A. Demopulos
Employees
175
Employees175
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1994
Founded1994
Employees
175
Employees175

OMER Key Statistics

Market cap
929.15M
Market cap929.15M
Price-Earnings ratio
10.77
Price-Earnings ratio10.77
Dividend yield
Dividend yield
Average volume
1.49M
Average volume1.49M
High today
$11.27
High today$11.27
Low today
$10.58
Low today$10.58
Open price
$11.10
Open price$11.10
Volume
1.24M
Volume1.24M
52 Week high
$17.65
52 Week high$17.65
52 Week low
$3.44
52 Week low$3.44

Stock Snapshot

Omeros(OMER) stock is priced at $10.97, giving the company a market capitalization of 929.15M. It carries a P/E multiple of 10.77.

On 2026-07-28, Omeros(OMER) stock traded between a low of $10.58 and a high of $11.27. Shares are currently priced at $10.97, which is +3.7% above the low and -2.6% below the high.

Omeros(OMER) shares are trading with a volume of 1.24M, against a daily average of 1.49M.

In the last year, Omeros(OMER) shares hit a 52-week high of $17.65 and a 52-week low of $3.44.

In the last year, Omeros(OMER) shares hit a 52-week high of $17.65 and a 52-week low of $3.44.

OMER News

TipRanks 1d
Omeros Buy Rating Reiterated as Ultomiris Setback Eases Competitive Risk; $33 Price Target Maintained

Omeros, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on the...

TipRanks 1d
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transp...

People also own

Based on the portfolios of people who own OMER. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.